ST.
PAUL, Minn., Jan. 8, 2025
/PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf
Manufacturing and Bio-Techne Corporation, today announced that
Seattle Children's Therapeutics, a division of the Seattle
Children's Research Institute has been awarded a $125,000 G-Rex Grant. The G-Rex Grant will
integrate state-of-the-art advancements into Seattle Children's
Therapeutics' G-Rex based CAR-T cell platform.
"This technology has been a core component of our CAR-T platform
for many years, and we have manufactured cell therapy products for
hundreds of clinical trial participants using G-Rex bioreactors,"
said Christopher Brown, Director of
GMP Manufacturing at Seattle Children's Therapeutics.
"Seattle Children's was an early adopter of G-Rex and is
comprised of world-class scientists, physicians, and engineers who
bring hope to cancer patients," said John
Wilson, CEO of Wilson Wolf
and co-inventor of G-Rex. "I'm happy to see them take advantage of
our G-Rex Grant Program to further simplify the manufacture of
their groundbreaking therapies."
As part of the G-Rex Grant, Seattle Children's Therapeutics will
examine the full array of fully closed G-Rex bioreactors, as well
as the broad range of Bio-Techne's GMP-grade cytokines, with the
aim to optimize manufacturing for future CAR-T and other
trials. In addition, under the G-Rex Grant, Seattle
Children's Therapeutics will gain early access to the G-Rex product
development pipeline and will participate in early evaluation of
new G-Rex devices. This will also include assessment of G-Rex cell
separation technology that isolates T-cells within a G-Rex
bioreactor without need of expensive instrumentation.
ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and
gene-modified cell therapy (CGT) development and manufacturing by
awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain
access to exclusive support from ScaleReady's growing consortium of
G-Rex Grant Partners who bring best-in-class tools and technologies
as well as unparalleled knowledge and expertise in the areas of
cGMP manufacturing, quality and regulatory affairs, CGT business
operations, and more.
For more information about the G-Rex® Grant Program, please
contact info@scaleready.com.
About ScaleReady
ScaleReady provides the field of cell
and gene-modified cell therapy (CGT) with a G-Rex centric
manufacturing platform that enables the world's most practical,
flexible, scalable, and affordable CGT drug product development and
manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly
growing list of over 800 organizations and is producing drug
products for approximately 50% of CGT clinical trials as well as 5
commercially approved CGT drugs.
CGT entities relying on the breadth and scope of ScaleReady's
expertise can expect to save years of time and millions of dollars
on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program,
please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to
simplifying cell and gene-modified cell (CGT) therapy research,
process development, and manufacturing. This is being
accomplished through its scalable G-Rex technology, which is used
throughout the world in CGT applications ranging from basic
research to commercial drug production.
Wilson Wolf's mission is to
create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation
(NASDAQ: TECH) is a global life sciences company providing
innovative tools and bioactive reagents for the research and
clinical diagnostic communities. Bio-Techne, in partnership with
Wilson Wolf, is creating products
such as media and cytokines that are specifically tailored to
G-Rex® Bioreactors, including right-sized reagent quantities in
containers that are tailored to high throughput closed-system
manufacturing. For more information on Bio-Techne and its brands,
please visit https://www.bio-techne.com or follow the Company on
social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-seattle-childrens-therapeutics-302345266.html
SOURCE Bio-Techne Corporation